No Data
No Data
Shenyang Xingqi Pharmaceutical (300573.SZ): No research, production, or sales of ophthalmic related medical instruments currently.
Gelonghui reported on December 18 that Shenyang Xingqi Pharmaceutical (300573.SZ) stated on the investor interaction platform that the company continues to focus on the ophthalmology field and adheres to a specialized development path, currently not engaged in the research, production, and sales of ophthalmic-related medical instruments. In the future, the company will formulate strategies for industrial extension and collaborative development based on its own development circumstances in conjunction with the company's Global Strategy.
Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Jumps 3.9% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
Shenyang Xingqi Pharmaceutical (300573.SZ): A total of 37 products continue to be included in the national medical insurance directory.
On November 29, Glory Exchange reported that Shenyang Xingqi Pharmaceutical (300573.SZ) announced that on November 28, 2024, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security published the "Notice on Printing and Distributing the <National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Pharmaceutical Catalog (2024)>" (Healthcare Document [2024] No. 33). This time, the company has 37 products continuing to be included in the National Medical Insurance Catalog, including 8 in Category A and 29 in Category B. Products such as Cyclosporine Eye Drops (II), Compound Electrolyte Eye Irrigation Solution, and Sodium Hyaluronate Eye Drops continue to be included in the "National Medical Insurance Catalog"; this time, the company has none.
Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) Market Cap Dropped CN¥854m Last Week; Retail Investors Bore the Brunt
Shenyang Xingqi Pharmaceutical (300573.SZ): The IV phase clinical research report was obtained after the listing of cyclosporine eye drops (II).
Galonnay November 12th | shenyang xingqi pharmaceutical (300573.SZ) announced that the company's product Ciclosporin Eye Drops (Ⅱ) has recently obtained the Phase IV clinical research report on the safety and effectiveness of Ciclosporin Eye Drops (Ⅱ) in the treatment of dry eye. The company's Ciclosporin Eye Drops (Ⅱ) has obtained the Pharmaceutical Registration Certificate. As of the date of the announcement, according to the National Medical Products Administration website, the company's Ciclosporin Eye Drops (Ⅱ) is the only domestically approved Ciclosporin ophthalmic preparation for the treatment of dry eye. This study is a multicenter, prospective clinical trial with 1,999 subjects over a period of time.
shenyang xingqi pharmaceutical (300573.SZ): Loratadine hydrochloride eye drops obtained pharmaceutical registration certificate.
Shenyang Xingqi Pharmaceutical (300573.SZ) announced that recently, the company has received the approved issued by the National Medical Products Administration (NMPA) for Olopatadine Hydrochloride Eye Drops "Drug Registration Certificate". This product is an eye drop with Olopatadine Hydrochloride as the main ingredient. The Olopatadine Hydrochloride eye drops approved this time by the company are multi-dose products, clinically indicated for treating eye itching related to allergic conjunctivitis.
Market Participants Recognise Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) Revenues Pushing Shares 26% Higher
No Data
